₹1,711.2
▼ -20.08 -1.16%
29 Jul 2026
NSE Listed · Pharmaceuticals
Onesource Specl Pharma Limited (ONESOURCE)
Volume: 22,339Avg Vol 1W: 2,76,426Avg Vol 1M: 3,16,57352W Range:₹1,057₹2,026.5
Key Ratios
Checked just nowMarket Cap₹19,618 Cr
Current Price₹1,711.2
Previous Close₹1,731.28
High / Low (52w)₹2,026.5 / ₹1,057
Volume22,339
Avg Vol (1W)2,76,426
Avg Vol (1M)3,16,573
Stock P/E4,278
Book Value₹508.84
Dividend Yield0%
ROE-1.1%
ROA-0.9%
Revenue (TTM)—
Revenue Growth7.4%
Profit Margin-5.19%
Total Debt₹219 Cr
Shares Outstanding11 Cr
Face Value₹1
EPS (TTM)₹0.4
P/B3.36
Debt / Equity0.26
50 DMA₹1,693.95
200 DMA₹1,619.64
Day change-1.16%
Price Chart
₹1,711.2▼ 13.11% · 1Y
2025-07-292026-07-29
20-day avg volume: 3.4L shares
Pros
- Company is almost debt-free.
- Net profit is growing year over year.
Cons
- Stock trades at a high P/E of 4278.
Quarterly Results
| Metric | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹334 Cr | ₹393 Cr | ₹426 Cr | ₹327 Cr | ₹376 Cr | ₹290 Cr | ₹428 Cr | ₹449 Cr |
| EBITDA | ₹13 Cr | ₹80 Cr | ₹117 Cr | ₹26 Cr | ₹40 Cr | ₹-48 Cr | ₹22 Cr | ₹55 Cr |
| Net Profit | ₹-42 Cr | ₹-69 Cr | ₹99 Cr | ₹0 Cr | ₹10 Cr | ₹-89 Cr | ₹5 Cr | ₹25 Cr |
| EPS | — | — | — | — | — | — | — | — |
Profit & Loss (Annual)
| Metric | Dec 2024 | Mar 2025 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹337 Cr | ₹1,462 Cr | ₹477 Cr | ₹321 Cr | ₹375 Cr | ₹290 Cr | ₹419 Cr | ₹446 Cr |
| EBITDA | ₹71 Cr | ₹210 Cr | ₹207 Cr | ₹52 Cr | ₹70 Cr | ₹-17 Cr | ₹42 Cr | ₹82 Cr |
| Net Profit | ₹-73 Cr | ₹-18 Cr | ₹174 Cr | ₹25 Cr | ₹37 Cr | ₹-62 Cr | ₹21 Cr | ₹51 Cr |
| EPS | — | -1.63 | — | — | — | — | — | — |
Balance Sheet
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Total Assets | ₹971 Cr | ₹1,258 Cr | ₹2,442 Cr | ₹2,009 Cr | ₹1,309 Cr | ₹7,550 Cr |
| Total Liabilities | ₹554 Cr | ₹482 Cr | ₹1,430 Cr | ₹1,223 Cr | ₹913 Cr | ₹1,670 Cr |
| Equity | ₹417 Cr | ₹776 Cr | ₹1,012 Cr | ₹785 Cr | ₹396 Cr | ₹5,881 Cr |
| Total Debt | — | — | — | — | — | — |
Cash Flow
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Operating | ₹-52 Cr | ₹-117 Cr | ₹-416 Cr | ₹-174 Cr | ₹-107 Cr | ₹-61 Cr |
| Investing | ₹-157 Cr | ₹-207 Cr | ₹-692 Cr | ₹-68 Cr | ₹511 Cr | ₹-201 Cr |
| Financing | ₹65 Cr | ₹381 Cr | ₹1,162 Cr | ₹118 Cr | ₹-391 Cr | ₹412 Cr |
| Free Cash Flow | ₹-52 Cr | ₹-117 Cr | ₹-416 Cr | ₹-218 Cr | ₹-171 Cr | ₹-189 Cr |
Shareholding
Promoter 30.48% Institutions 42.58% Public 26.95%
Efficiency & Working Capital
ROCE5.2%
Interest Coverage1.3
Dividend Payout—
Debtor Days105 d
Inventory Days40 d
Payable Days44 d
Cash Conversion Cycle101 d
Working Capital Days145 d
Shareholding Details
As of 2026-06-30
Promoter30.5%
FII19.2%
DII23.4%
Institutions42.6%
Public26.9%
Promoter Pledge37.2%
No. of Shareholders77,899
Shareholding Pattern
Quarterly — figures in %. Latest 7 quarters.
| Period | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|
| Promoters | 37.8% | 34.3% | 29.8% | 29.8% | 29.9% | 30.5% | 30.5% |
| FIIs | 17.4% | 18.5% | 18.7% | 19.4% | 19.2% | 17.5% | 19.2% |
| DIIs | 12.6% | 18% | 18.1% | 18.5% | 18.8% | 20.6% | 23.4% |
| Public | 32.2% | 29.2% | 33.4% | 32.4% | 32% | 31.4% | 26.9% |
| Promoter Pledge | 9.6% | 20.1% | 25% | 26% | 18.5% | 38.4% | 37.2% |
| No. of Shareholders | 98,425 | 82,712 | 87,760 | 87,416 | 84,595 | 79,460 | 77,899 |
Returns History (ROE / ROCE / ROA)
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202503 | — | — | — | — |
Major Shareholders (>1%)
| Name | Category | Stake | Shares |
|---|---|---|---|
| Tenshi Pharmaceuticals Private Limited | Shareholding of Promoter and Promoter Group | 18.4% | 2.11 Cr |
| Karuna Business Solutions Llp | Shareholding of Promoter and Promoter Group | 7.1% | 80,90,353 |
| Motilal Oswal Mutual Fund | Public Shareholding | 7.1% | 80,94,694 |
| Authum Investment And Infrastructure Limited | Public Shareholding | 5% | 56,81,844 |
| Pronomz Ventures Llp | Shareholding of Promoter and Promoter Group | 2.4% | 27,61,308 |
| Route One Offshore Master Fund L.p. | Public Shareholding | 2.3% | 26,63,310 |
| Route One Fund I, L.p. | Public Shareholding | 2.1% | 23,68,534 |
| Sbi Life Insurance Co. Ltd | Public Shareholding | 2.1% | 23,67,124 |
| Amansa Holdings Private Limited | Public Shareholding | 1.9% | 21,31,912 |
| Think Investments Pcc | Public Shareholding | 1.8% | 20,49,497 |
| Fidelity Securities Fund: Fidelity Blue Chip Growth Fund | Public Shareholding | 1.8% | 20,20,423 |
| 360 One Special Opportunities Fund - Series 12 | Public Shareholding | 1.6% | 18,52,688 |
| Arco Lab Private Limited | Shareholding of Promoter and Promoter Group | 1.6% | 18,39,900 |
| Axis Mutual Fund | Public Shareholding | 1.3% | 15,28,296 |
| Timf Holdings | Public Shareholding | 1.3% | 14,39,656 |
| Mirae Asset | Public Shareholding | 1.2% | 13,98,263 |
| Arun Kumar Pillai | Shareholding of Promoter and Promoter Group | 0.9% | 9,70,497 |
| Padmakumar Karunakaran Pillai | Shareholding of Promoter and Promoter Group | 0% | 43,242 |
| Vineetha Mohanakumar Pillai | Shareholding of Promoter and Promoter Group | 0% | 47,500 |
| Rajitha Gopalakrishnan | Shareholding of Promoter and Promoter Group | 0% | 30,000 |
| Sajitha Pillai | Shareholding of Promoter and Promoter Group | 0% | 35,000 |
| Aditya Arun Kumar | Shareholding of Promoter and Promoter Group | 0% | 29,211 |
| Hemalatha Pillai | Shareholding of Promoter and Promoter Group | 0% | 3,380 |
Promoter Pledges
| Holder | Pledged Shares | % of Holding | As of |
|---|---|---|---|
| Karuna Business Solutions Llp | 25,36,695 | 31.4% | 2026-06-30 |
| Tenshi Pharmaceuticals Private Limited | 1.03 Cr | 48.7% | 2026-06-30 |
| Pronomz Ventures Llp | 2,07,204 | 7.5% | 2026-06-30 |
Board of Directors
| Name | Designation | Year |
|---|---|---|
| Arun Kumar | Chairman & Non Executive Dir. | 2025 |
| Neeraj Sharma | Managing Director & CEO | 2025 |
| Debarati Sen | Independent Non Exe. Director | 2025 |
| Claudio Albrecht | Independent Non Exe. Director | 2025 |
| Rashmi Harshadrai Barbhaiya | Independent Non Exe. Director | 2025 |
| Vijay Paul Karwal | Independent Non Exe. Director | 2025 |
| Colin Michael Bond | Independent Non Exe. Director | 2025 |
| Bharat Shah | Non Executive Director | 2025 |
| Trisha A | Company Sec. & Compli. Officer | 2025 |
Segments — Product
| Segment | Revenue | Share |
|---|---|---|
| CDMO | ₹1,300 Cr | 100% |
| Unit 3 : Multimodal facility and CD | ₹0 Cr | 0% |
Segments — Geography
| Region | Revenue | Share |
|---|---|---|
| India | ₹194 Cr | 14.9% |
| Singapore | ₹668 Cr | 51.4% |
| Outside India | ₹438 Cr | 33.7% |
Capital Structure (₹ Cr)
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2025 | ₹1 | 15 | 11 | 11 |
Corporate Actions
| Type | Date | Value | Remark |
|---|---|---|---|
| forthcoming | 2026-07-24 | Board Meetings | — |
Related-Party Transactions (₹ Cr)
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2025 | 1,018 | 0 | 0 | 9 | 577 | 1,604 |
| 2025 | 11 | 0 | 0 | 0 | 67 | 78 |
| 2025 | 360 | 0 | 0 | 9 | 382 | 751 |
Insider / Designated-Person Trades
6 recent disclosure(s)
Tenshi Pharmaceuticals Private LimitedAcquisition · 2,00,000
TENSHI PHARMACEUTICALS PRIVATE LIMITEDAcquisition · 85,000
TENSHI PHARMACEUTICALS PRIVATE LIMITEDAcquisition · 75,000
TENSHI PHARMACEUTICALS PRIVATE LIMITEDAcquisition · 2,05,000
PRONOMZ VENTURES LLPAcquisition · 45,000
PRONOMZ VENTURES LLPAcquisition · 33,906
Substantial Acquisitions (SAST)
6 disclosure(s)
Market04/02/2026 · 85,000
Market02/02/2026 · 2,05,000
Market02/02/2026 · 45,000
Market30/01/2026 · 75,000
Market30/01/2026 · 33,906
Market28/01/2026 · 2,00,000
Company Information
Incorporated2007
ChairmanArun Kumar
AuditorDeloitte Haskins & Sells/BSR & Co LLP
Investor Email[email protected]
📍 201 Devarata Sector 17 Vashi, Navi Mumbai Sanpada, Thane, Maharashtra, 400703
Technical AnalysisPremium
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Om Infra LimitedOmnitech Engineering Ltd.Om Power Transmission Ltd.On Door Concepts LimitedOnelife Capital Advisors Ltd.One Point One Solutions Ltd.Oil & Natural Gas Corpn Ltd.OnMobile Global Ltd.Onward Technologies Ltd.Onyx Biotec LimitedOptiemus Infracom Ltd.Optivalue Tek Consulting Ltd.All “O” stocks →
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search